DDInter416 DDInter1229
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significant antimuscarinic activity, which is responsible both for the therapeutic effects of these medications and their broad range of adverse effects. Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its use alongside solifenacin in refractory cases. Mirabegron first received FDA approval in 2012, under the brand name Myrbetriq, for the treatment of adults with overactive bladder. An extended-release granule formulation was subsequently granted approval in March 2021 for the treatment of pediatric patients with neurogenic detrusor overactivity. Mirabegron is also used in other jurisdictions across the globe, including Canada, the EU, and Japan.
Clotrimazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Mirabegron
Clotrimazole {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Clotrimazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Propafenone
Propafenone {u} (Compound) resembles {v} (Compound) Mirabegron
Clotrimazole {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Propafenone
Propafenone {u} (Compound) resembles {v} (Compound) Mirabegron
Clotrimazole {u} (Compound) causes {v} (Side Effect) Bladder pain
Bladder pain {u} (Side Effect) is caused by {v} (Compound) Trospium
Trospium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mirabegron
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Trospium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mirabegron
Clotrimazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Clotrimazole {u} (Compound) causes {v} (Side Effect) Abdominal distension
Abdominal distension {u} (Side Effect) is caused by {v} (Compound) Aprepitant
Aprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenidol
Diphenidol {u} (Compound) resembles {v} (Compound) Trospium
Trospium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mirabegron
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Mirabegron
Clotrimazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mirabegron (Compound)
Clotrimazole (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Mirabegron (Compound)
Clotrimazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Propafenone (Compound) and Propafenone (Compound) resembles Mirabegron (Compound)
Clotrimazole (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Propafenone (Compound) and Propafenone (Compound) resembles Mirabegron (Compound)
Clotrimazole (Compound) causes Bladder pain (Side Effect) and Bladder pain (Side Effect) is caused by Trospium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron
Clotrimazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Clotrimazole (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Aprepitant (Compound) and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Clotrimazole (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Trospium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mirabegron (Compound)